Abstract:Stabilization of a G-quadruplex (G4) in the promotor of the c-MYC proto-oncogene leads to inhibition of gene expression, and it thus represents a potentially attractive new strategy for cancer treatment. However, most G4 stabilizers show little selectivity among the many G4s present in the cellular complement of DNA and RNA. Intriguingly, a crescent-shaped cell-penetrating thiazole peptide, TH3, preferentially stabilizes the c-MYC G4 over other promotor G4s, but the mechanisms leading to this selective binding remain obscure. To investigate these mechanisms at the atomic level, we performed an in silico comparative investigation of the binding of TH3 and its analogue TH1 to the G4s from the promotors of c-MYC, c-KIT1, c-KIT2, and BCL2. Molecular docking and molecular dynamics simulations, combined with in-depth analyses of non-covalent interactions and bulk and per-nucleotide binding free energies, revealed that both TH3 and TH1 can induce the formation of a sandwich-like framework through stacking with both the top and bottom G-tetrads of the c-MYC G4 and the adjacent terminal capping nucleotides. This framework produces enhanced binding affinities for c-MYC G4 relative to other promotor G4s, with TH3 exhibiting an outstanding binding priority. Van der Waals interactions were identified to be the key factor in complex formation in all cases. Collectively, our findings fully agree with available experimental data. Therefore, the identified mechanisms leading to specific binding of TH3 towards c-MYC G4 provide valuable information to guide the development of new selective G4 stabilizers.

Molecular Insights into the Specific Targeting of c-MYC G-Quadruplex by Thiazole Peptides

Insight Derived from Molecular Dynamics Simulation into the Selectivity Mechanism Targeting C-Myc G-Quadruplex

Cell penetrating thiazole peptides inhibit c-MYC expression via site-specific targeting of c-MYC G-quadruplex

Distinguishing G-Quadruplexes Stabilizer and Chaperone for C-Myc Promoter G-Quadruplexes Through Single-Molecule Manipulation.

Constructing triazole-modified quinazoline derivatives as selective c-MYC G-quadruplex ligands and potent anticancer agents through click chemistry

Rational design of small-molecules to recognize G-quadruplexes of c-MYC promoter and telomere and the evaluation of their in vivo antitumor activity against breast cancer

Discovery of a New Four-Leaf Clover-Like Ligand as a Potent c-MYC Transcription Inhibitor Specifically Targeting the Promoter G-Quadruplex.

Human Myc G-Quadruplex: From Discovery To A Cancer Therapeutic Target

Design, Synthesis, and Evaluation of New Selective NM23-H2 Binders as c-MYC Transcription Inhibitors via Disruption of the NM23-H2/G-Quadruplex Interaction

Non-fused imidazole-biphenyl analogs repress triple-negative breast cancer growth by mainly stabilizing the c-MYC G-quadruplex via a multi-site binding mode

Design, Synthesis, and Evaluation of New Sugar-Substituted Imidazole Derivatives As Selective C-Myc Transcription Repressors Targeting the Promoter G-Quadruplex.

Structure of G-Quadruplex in the Oncogene c-myc Promoter and Small Ligands Targeting the G-Quadruplex

Target guided synthesis using DNA nano-templates for selectively assembling a G-quadruplex binding c-MYC inhibitor

A Drug-Like Imidazole-Benzothiazole Conjugate Inhibits Malignant Melanoma by Stabilizing the C-Myc G-quadruplex.

Stabilization of G-Quadruplex DNA and Down-Regulation of Oncogene<i>c</i>-<i>myc</i>by Quindoline Derivatives

Identification of Sanguinarine As C-Myc Transcription Inhibitor Through Enhancing the G-quadruplex-NM23-H2 Interactions

G-Quadruplexes in c-MYC Promoter as Targets for Cancer Therapy

Stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc by quindoline derivatives.

Solution Structures and Effects of a Platinum Compound Successively Bound MYC G-quadruplex.

Visualization of Ligand-Induced C-Myc Duplex-Quadruplex Transition and Direct Exploration of the Altered C-Myc DNA-protein Interactions in Cells

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX